Amgen Inc. is a pioneering global biotechnology leader specializing in the discovery, development, and high-volume manufacturing of human genetics-based biologics. The company commands dominant therapeutic portfolios in bone health (Prolia), cardiovascular conditions (Repatha), and biosimilars. Backed by vast regulatory moats and steady cross-cycle pricing power, it functions as a highly defensive income-generating pharma asset.